Collective IP Analysis | BioMarin Acquisition of Prosensa

On November 24th rare disease drug maker BioMarin Pharmaceuticals¬†announced it was buying Prosensa¬†for $840MM plus approval milestones. Prosensa has no marketed products but is in the late stages of obtaining approval for its lead drug candidate, drisapersen, for a rare form of muscular dystrophy. BioMarin will pay Prosensa shareholders an additional $80MM if drisapersen receives… Read more »